Aminoglutethimide (Elipten-Ciba) as an inhibitor of adrenal steroidogenesis: mechanism of action and therapeutic trial.

Suppr

超能文献

作者信息

Cash R, Brough A J, Cohen M N, Satoh P S

出版信息

J Clin Endocrinol Metab. 1967 Sep;27(9):1239-48. doi: 10.1210/jcem-27-9-1239.

DOI:10.1210/jcem-27-9-1239

PMID:4292247

Abstract

摘要

相似文献

Aminoglutethimide (Elipten-Ciba) as an inhibitor of adrenal steroidogenesis: mechanism of action and therapeutic trial.

J Clin Endocrinol Metab. 1967 Sep;27(9):1239-48. doi: 10.1210/jcem-27-9-1239.

Inhibition of adrenal corticosteroid synthesis by aminoglutethimide: studies of the mechanism of action.

J Clin Endocrinol Metab. 1967 Apr;27(4):473-80. doi: 10.1210/jcem-27-4-473.

[Clinical and biological study of an inhibitor of adrenocortical hormone synthesis: aminoglutethinide].

Ann Endocrinol (Paris). 1968 Mar-Apr;29(2):189-210.

Effects of aminoglutethimide (Elipten Ciba), a steroid biosynthesis blocking agent, on adrenal glands in Cushing's syndrome.

Virchows Arch A Pathol Pathol Anat. 1973;360(1):11-26. doi: 10.1007/BF00548654.

[Agents inhibiting steroid biosynthesis--aminoglutethimide and o,p'-DDD].

Nihon Rinsho. 1974 Nov 10;32(11):3257-61.

Aminoglutethimide: a "side-effect" turned to therapeutic advantage.氨鲁米特：一种化“副作用”为治疗优势的药物。

Postgrad Med J. 1970 Jul;46(537):409-16. doi: 10.1136/pgmj.46.537.409.

Aminoglutethimide inhibition of adrenal desmolase activity.

Proc Soc Exp Biol Med. 1968 Apr;127(4):1086-90. doi: 10.3181/00379727-127-32877.

[Corticosteroidogenesis inhibitors. II. A new cortico-adrenal inhibitor: amino-glutethimide (16,038Ba)].[皮质类固醇生成抑制剂。II. 一种新的肾上腺皮质抑制剂：氨基谷氨酰胺（16,038Ba）]

Presse Med (1893). 1968 May 11;76(23):1107-10.

[Clinical experiences with aminoglutethimide (Elipten), a new inhibitor of steroid biosynthesis in the adrenal gland].

Schweiz Med Wochenschr. 1968 Nov 23;98(47):1843-51.

Successful medical adrenalectomy with amino-glutethimide. Role of altered drug metabolism.用氨鲁米特成功进行肾上腺切除术。药物代谢改变的作用。

JAMA. 1974;230(12):1661-5.

引用本文的文献

Targeting Oestrogen Receptor Signalling in Breast Cancer Therapy.靶向雌激素受体信号传导在乳腺癌治疗中的应用

Adv Exp Med Biol. 2025;1464:449-474. doi: 10.1007/978-3-031-70875-6_22.

Aromatase enzyme: Paving the way for exploring aromatization for cardio-renal protection.芳香化酶：探索芳香化作用以保护心肾的途径。

Biomed Pharmacother. 2023 Dec;168:115832. doi: 10.1016/j.biopha.2023.115832. Epub 2023 Nov 6.

Identification of candidate reference chemicals for in vitro steroidogenesis assays.鉴定用于体外类固醇生成测定的候选参比化学品。

Toxicol In Vitro. 2018 Mar;47:103-119. doi: 10.1016/j.tiv.2017.11.003. Epub 2017 Nov 13.

Aromatase inhibition 2013: clinical state of the art and questions that remain to be solved.芳香酶抑制 2013：临床最新技术和仍待解决的问题。

Endocr Relat Cancer. 2013 Jun 24;20(4):R183-201. doi: 10.1530/ERC-13-0099. Print 2013 Aug.

The potency and clinical efficacy of aromatase inhibitors across the breast cancer continuum.芳香酶抑制剂在乳腺癌全程治疗中的作用和临床疗效。

Ann Oncol. 2011 Mar;22(3):503-514. doi: 10.1093/annonc/mdq337. Epub 2010 Jul 8.

Aromatase inhibitors: past, present and future in breast cancer therapy.芳香化酶抑制剂：乳腺癌治疗的过去、现在与未来

Med Oncol. 2008;25(2):113-24. doi: 10.1007/s12032-007-9019-x. Epub 2007 Nov 1.

Aromatase inhibitors for breast cancer.用于乳腺癌的芳香化酶抑制剂

Rev Endocr Metab Disord. 2007 Sep;8(3):215-28. doi: 10.1007/s11154-007-9039-z.

Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer.针对雌激素受体用于治疗和预防乳腺癌的疗法的发展与演变。

Steroids. 2007 Jan;72(1):7-25. doi: 10.1016/j.steroids.2006.10.009. Epub 2006 Dec 13.

Involvement of steroids in anti-inflammatory effects of PK11195 in a murine model of pleurisy.在小鼠胸膜炎模型中，类固醇参与PK11195的抗炎作用。

Mediators Inflamm. 2004 Apr;13(2):93-103. doi: 10.1080/09629350410001688486.

Clinical pharmacokinetics of aromatase inhibitors and inactivators.芳香化酶抑制剂和灭活剂的临床药代动力学

Clin Pharmacokinet. 2003;42(7):619-31. doi: 10.2165/00003088-200342070-00002.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验